EUCTR2016-000113-70-GB进行中（未招募）1 期
Clinical efficacy and mechanistic evaluation of Eplerenone for Central serous chorio-retinopathy – the VICI randomised trial. - VICI
niversity Hospital Southampton NHS Foundation Trust0 个研究点目标入组 104 人开始时间: 2020年6月11日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 104
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Participant may enter study if ALL of the following apply
- •1.Participants will be aged =18 years and = 60 years
- •2.Visual impairment due to CSCR of = 4 months duration defined as:
- •a.subfoveal presence of SRF on OCT
- •b.characteristic appearance of CSCR on FFA and Indocyanine-green angiography (ICGA).
- •c.investigator believes that there is sufficient evidence from either patient history, case note documentation or appearance of the macula that CSCR has been present for at least 4 months.
- •3.Women must have a negative pregnancy test and be willing to use effective contraception* for the duration of the participation in the trial and for 3 months after, be surgically sterile or post-menopausal for >12 months.
- •4.Able to provide written informed consent.
- •The following apply to the study eye:
- •5.A study eye should have an Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA score greater than 53 letters and less than 86 letters.
- •6.A study eye should have clear ocular media and adequate pupillary dilatation to permit photography.
- •* this includes: progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action, male or female condom with or without spermicide cap, diaphragm or sponge with spermicide, combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal),
- •progestogen-only hormonal contraception associated with inhibition of ovulation: (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, vasectomised partner, sexual abstinence.
- •NB pregnancy test only need to be repeated if there is reason to suspect the participant has become pregnant.
- •There are no special precautions/contraceptive requirements for male participants with female partners of child bearing potential.
- •It is rare but not impossible for patients to present with CSCR in both eyes or CSCR may develop in the fellow eye during the trial. We propose to measure eye-specific outcomes such as BCVA in both eyes throughout the trial, designating eyes as study eyes or not. Statistical analyses will take into account the availability of data for two eligible eyes in one patient.
- •If both eyes present with CSCR at baseline, the clinical trial site will decide which is the primary eye and this eye will have retinal imaging performed first. The primary eye would usually be the one with most active disease/most sub-retinal fluid. It will be identified by OCT imaging and subsequent investigations such as fluorescein and indocyanine green angiography will then be performed initially on this eye. If a patient presents with one affected eye and the fellow eye subsequently develops CSCR the eye first affected will always be the primary study eye.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 104
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •Participant may not enter study if ANY of the following apply
- •1.Hyperkalaemia (serum potassium level > 5.0 mmol/L).
- •2.Hepatic or renal impairment (Patients with severe renal insufficiency (Estimated glomerular filtration rate, eGFR < 30 mL per minute per 1.73 m2) or Patients with severe hepatic insufficiency (Child-Pugh Class C).
- •3.Pregnancy or breast feeding.
- •4.Known allergy to fluorescein or indocyanine green.
- •5.Patients receiving potassium-sparing diuretics, potassium-supplements, or inhibitors of CYP 3A4 (e.g.amiodarone, diltiazem, fluconazole, itraconazole, ketoconazole, ritonavir, nelfinavir, saquinavir clarithromycin, telithromycin, erythromycin, verapamil, spironolactone and nefazodone)).Patients taking furosemide are eligible.
- •6.Patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g. ibuprofen, naproxen).
- •7.Patients receiving the combination of an angiotensin converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) with eplerenone.
- •8.Patients receiving lithium, cyclosporine or tacrolimus.
- •9.Hypersensitivity or known allergy to eplerenone or to any of the excipients.
- •10.Known hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption
- •11. Patients receiving high doses of Aspirin (>75mg).
- •The following additional exclusions apply to a study eye only (i.e. they may be present for a non-study eye):
- •12.Evidence of choroidal neovascularization.
- •13.Previous or current treatment with eplerenone for any reason or previous or current treatment with photodynamic laser therapy / any anti-VEGF therapy in the study eye / any intra-ocular steroid use / thermal laser therapy for CSCR
- •14.Presence of any other disease which could cause retinal or SRF to accumulate e.g. diabetic retinopathy, polypoidal choroidal vasculopathy, domed shaped maculopathy or choroidal hemangioma or affect visual acuity.
- •15.Myopia > -6 dioptres
研究者
相似试验
招募中
不适用
Comparative investigation of clinical utility of EMLA cream and lidocaine tape at laser therapyAngioma, nevus, mole, seborrheic keratosis, senile lentigo, tattooJPRN-UMIN000011515Juntendo University School of Medicine40
已完成
1 期
Evaluation of efficacy and safety of Ebola vaccine iEvac-Z in humaJPRN-jRCTs031190118Koga Michiko30
尚未招募
2 期
Ayurveda management of Chronic tonsillitis in childreCTRI/2020/08/027344SDM College of Ayurveda and Hospital
招募中
不适用
Clinical study for the systematic application of eCBTI and acupuncture in the treatment of chronic insomniaInsomniaITMCTR2000003306Jiangsu Province Traditional Chinese Medicine Hospital
已完成
不适用
Observational study on the therapeutic effect of endoscopic stent placement for malignant gastroduodenal obstructioMalignant gastroduodenal obstructionJPRN-UMIN000026193Kanazawa University Hospital Department of Gastroenterology200